Illumina and Sanuo Biotech Announce Strategic Collaboration to Localize iScan® Chip Scanner and Expand Genomic Applications in Precision Health Management

ChangshaJanuary 9, 2024PR Newswire -- Yesterday, Illumina, Inc., the global leader in gene sequencing and chip technology, and Sinocare Inc., a global leader in digital diabetes management (hereinafter referred to as "Sinocare"), officially announced a strategic partnership. The collaboration will focus on iScan.^®Starting with the localization of high-end chip scanners in China, both parties will leverage their technical advantages and channel resources to jointly expand the application of genomics in precision health management. This collaboration aims to meet the demands of the Chinese domestic market in areas such as reproductive genetics and chronic disease prevention and treatment more quickly and effectively, contributing to the realization of the "Healthy China" strategy and the high-quality development of national health.

Haiyan Ma, Vice President of Sales, Illumina China, and Acting General Manager of Greater China"For a long time, Illumina has been closely following and actively participating in the high-quality development process of China's national health initiatives. By promoting extensive local collaborations, we continuously accelerate the availability of high-quality products to meet the evolving health needs of Chinese society. This new partnership with Sinocare not only represents a new breakthrough in our localization strategy and diverse product portfolio but also serves as a new attempt to empower local innovation models. Moreover, it is a new action and leap based on the shared vision of 'improving human health.' Looking ahead, we look forward to collaborating with Sinocare to explore more precision health management solutions that align with local needs in China, jointly promoting the high-quality development of public health."

Chairman of Sinocare Inc., Li ShaoboSaid: "We are delighted to partner with Illumina, starting from the iScan^®Starting with this high-end chip scanner, which has mature market application experience, we will accelerate the localization of this product to meet the rapidly developing market demands. At the same time, based on this cooperative foundation, we look forward to jointly expanding health management solutions that meet China's local needs, providing technical support to enhance the capability for early disease prevention and monitoring. By leveraging advancements in genomics, we aim to unlock the potential of health market applications, and together, contribute to elevating the construction of "Healthy China" to new heights.

Signing Ceremony

In recent years, against the backdrop of an aging population and a decline in newborns, China has been actively promoting strategies for the prevention and treatment of chronic diseases, better birth and child-rearing, and healthy development. Comprehensive measures have been implemented across multiple areas, including risk assessment for chronic diseases such as diabetes, personalized diagnosis and treatment, precision health management, and a three-level prevention strategy for birth defects, to comprehensively advance the "Healthy China" initiative and enhance the public's sense of health and life satisfaction.

iScan® Chip Scanner Debuts at the Signing Ceremony

iScan^®The iScan chip scanner offers advantages such as high throughput, high sensitivity, and stable output of high-quality data. It is suitable for various microarray applications, including gene expression analysis, genotyping, and methylation analysis.^®Supporting multiple chip formats and types, the system and its solutions are scalable and capable of automated configuration, meeting experimental needs across different fields, scales, and purposes. It allows for customized experimental design and setup, offering researchers flexible and extensive experimental options. Currently, this product plays a significant role globally in exploring the genetic basis of complex diseases, assisting agricultural breeding decisions, and conducting whole-epigenome association studies. It also demonstrates application potential in precision health management.